NCT02560974 - A Study of Capecitabine (Xeloda) in Combination Chemotherapy Versus Surgery Alone in Participants With Gastric Cancer | Biotech Hunter

Enrollment

1,035

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions

Gastric Cancer

Interventions

DRUG

Capecitabine

Capecitabine will be administered orally at 1000 mg/m\^2 BID on Days 1 to 15 of a 3-week cycle, for 8 cycles.

DRUG

Oxaliplatin

Oxaliplatin will be administered as an IV infusion, 130 mg/m\^2 on Day 1 of each 3-week cycle for 8 cycles.

Trial Locations (36)

104

Taipei

333

Taoyuan District

500

Changhua

704

Tainan City

10408

Gyeonggi-do

49267

Busan

58128

Jeollanam-do

100044

Beijing

100142

Beijing

110001

Shenyang

200025

Shanghai

200032

Shanghai

300060

Tianjin

350001

Fujian

510060

Guangzhou

510080

Guangzhou

463-802

Bundang City

700-712

Daegu

702-210

Daegu

Unknown

Daegu

Seoul

Suwon

Taipei

443-380

Gyeonggi-do

405-760

Incheon

561-712

Jeollabuk-do

03080

Seoul

120-752

Seoul

130-872

Seoul

134-791

Seoul

135-720

Seoul

139-709

Seoul

140-743

Seoul

152-703

Seoul

158-710

Seoul

00112

Taipei

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY